The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer.

被引：0
|
作者：
Hoang, Tung
Sutera, Philip
Nguyen, Triet
Chang, Jin Hee
Jagtap, Shreya
Song, Yang
Shetty, Amol
Chowdhury, Dipanwita
Chan, Aaron
Carrieri, Francesca Anna
Song, Daniel Y.
DeWeese, Theodore L.
Lafargue, Audrey
Van der Eecken, Kim
Ost, Fred Bunz Piet
Tran, Phuoc T.
Deek, Matthew
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Univ Maryland, Baltimore, MD USA
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Sch Med, Baltimore, MD USA
[6] Ghent Univ Hosp, Ghent, Belgium
[7] Univ Ghent, Ghent, Belgium
[8] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17077
引用
收藏
页数：1
相关论文
共 50 条
  • [21] APR-246 Enhances Chemo-Sensitivity via Activation of ROS-TAp73-Noxa in Esophageal Cancer with TP53 Missense Mutation
    Makino, Tomoki
    Kobayashi, Teruyuki
    Yamashita, Kotaro
    Saito, Takuro
    Tanaka, Koji
    Takahashi, Tsuyoshi
    Kurokawa, Yukinori
    Yamasaki, Makoto
    Nakajima, Kiyokazu
    Morii, Eiichi
    Eguchi, Hidetoshi
    Doki, Yuichiro
    CANCER SCIENCE, 2021, 112 : 432 - 432
  • [22] CIGARETTE SMOKING AND TP53 GENE MUTATIONS IN BLADDER CANCER.
    Samanic, C.
    Baris, D. R.
    Silverman, D. T.
    Platz, E. A.
    Strickland, P. T.
    Schwenn, M. R.
    Schned, A. T.
    Johnson, A. R.
    Kida, M.
    Jones, M. A.
    Nickerson, M. L.
    Rothman, N.
    Moore, L. E.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 175 : S4 - S4
  • [23] Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.
    Hammer, Liat
    Rebernick, Ryan
    McFarlane, Matthew
    Westbrook, Thomas
    Hazime, Munna
    Hammoud, Tanya
    Chiu, Pin-en
    Xavier, Owens
    Wu, Yi-Mi
    Robinson, Dan R.
    Spratt, Daniel Eidelberg
    Alva, Ajjai Shivaram
    Jackson, William C.
    Reichert, Zachery R.
    Alumkal, Joshi J.
    Chinnaiyan, Arul
    Cieslik, Marcin
    Dess, Robert Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [24] TP53 mutation screening in patients with recurrent platinum-sensitive ovarian cancer.
    Brana, Irene
    Moore, Kathleen
    Welch, Stephen
    Shapira-Frommer, Ronnie
    Gibbon, Darlene
    Hirte, Hal
    Rivkin, Saul
    Coleman, Robert
    Prendergast, Gerry
    Moxley, Katherine M.
    Jou, Ying-Ming
    Marinucci, Michelle
    Freshwater, Tomoko
    McCarthy, Sharon
    Anthony, Mark Lee
    Rose, Shelonitda
    Oza, Amit M.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [25] To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
    Sallman, David A.
    HAEMATOLOGICA, 2020, 105 (06) : 1470 - 1472
  • [26] Impact of TP53 mutations in Triple Negative Breast Cancer
    Zahi I. Mitri
    Nour Abuhadra
    Shaun M. Goodyear
    Evthokia A. Hobbs
    Andy Kaempf
    Alastair M. Thompson
    Stacy L. Moulder
    npj Precision Oncology, 6
  • [27] Impact of TP53 mutations in Triple Negative Breast Cancer
    Mitri, Zahi, I
    Abuhadra, Nour
    Goodyear, Shaun M.
    Hobbs, Evthokia A.
    Kaempf, Andy
    Thompson, Alastair M.
    Moulder, Stacy L.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [28] Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer
    Meric-Bernstam, Funda
    Zheng, Xiaofeng
    Shariati, Maryam
    Damodaran, Senthil
    Wathoo, Chetna
    Brusco, Lauren
    Demirhan, Mehmet Esat
    Tapia, Coya
    Eterovic, Agda Karina
    Basho, Reva K.
    Ueno, Naoto T.
    Janku, Filip
    Sahin, Aysegul
    Rodon, Jordi
    Broaddus, Russell
    Kim, Tae-Beom
    Mendelsohn, John
    Shaw, Kenna R. Mills
    Tripathy, Debu
    Mills, Gordon B.
    Chen, Ken
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 15
  • [29] Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
    Mitchell, Aaron Philip
    Mishra, Akriti A.
    Bach, Peter B.
    Morris, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [30] Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancer
    Netter, Jeanne
    Lehmann-Che, Jacqueline
    Lambert, Jerome
    Tallet, Anne
    Lourenco, Nelson
    Soliman, Hany
    Bertheau, Philippe
    Pariente, Benjamin
    Chirica, Mircea
    Pocard, Marc
    Allez, Matthieu
    De The, Hugues
    Gornet, Jean-Marc
    BULLETIN DU CANCER, 2015, 102 (02) : 117 - 125
12345